TBI-1501 / Jichi Medical University, Takara - LARVOL DELTA

Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1/2 | N=21 | Active, not recruiting | Sponsor: Takara Bio Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD19

Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1/2; N=21; Recruiting; Sponsor: Takara Bio Inc.

Clinical • New P1/2 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • CD19

Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1/2; N=21; Recruiting; Sponsor: Takara Bio Inc.; Trial completion date: Mar 2020 ➔ Mar 2035; Trial primary completion date: Mar 2019 ➔ Mar 2035

Clinical • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD19

Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1/2; N=21; Recruiting; Sponsor: Takara Bio Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • CD19

"#ASH16 #bmtworkshop16 Carl June now discussing future or CART "need to learn lessons of Dendreon"" - @DrMiguelPerales

Clinical • Conference • Oncology

Cytokine Release Syndrome and Tumor Responses in a First-in-Man Trial of a Novel Affinity-Enhanced TCR-Gene Transduced T Cell Transfer Targeting NY-ESO-1 Antigen (ASH 2017) - "...In CD19-CAR-T cell therapy, high incidence of cytokine release syndrome (CRS) is associated with in vivo CAR-T cell proliferation and its clinical efficacy...They were managed the treatment of anti-IL-6 receptor monoclonal antibody, tocilizumab...In one patient, progression-free survival lasted more than 8 months. In summary, the affinity-enhanced NY-ESO-1 TCR-T cell transfer exhibited CRSs in association with in vivo cell proliferation and sequential tumor responses."

CAR T-Cell Therapy • Biosimilar • Hematological Malignancies • Oncology • Sarcoma • Solid Tumor

CD19 chimeric antigen receptor T cell therapy: Approval and launch in Japan for adult ALL in FY2021 (Takara) - Annual Report 2017

Japanese regulatory • Launch Japan • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology